Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial
TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) today announced that the good manufacturing practice (GMP) production campaign for AB569 has been completed by Dalton Pharma Services.
Arch Biopartners Engages Nucro Technics to Begin Toxicology Studies for Metablok
TORONTO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro Technics in Scarborough, Ontario to perform preclinical toxicology and pharmacology studies for Metablok, the Company’s drug candidate for treating inflammation, cancer metastasis and sepsis.
TORONTO, ONTARIO--(Marketwired - Oct. 24, 2017) - Arch Biopartners Inc., ("Arch" or the "Company") (TSX VENTURE:ARCH)(OTCBB:ACHFF), announced it has closed a non-brokered, unsecured convertible note (the "Note") financing for gross proceeds of CAD $500,000 (the "Offering") on October 23, 2017.